Abstract:In the past decade, fludarabine has had a major impact in increasing the effectiveness of treatment of patients with indolent B-cell malignancies. This has come about in a variety of clinical circumstances, including use of fludarabine alone as well as in combinations with DNA-damaging agents or membrane-targeted antibodies. Other strategies have used fludarabine to reduce immunological function, thus facilitating non-myeloablative stem cell transplants.Fludarabine is a prodrug that is converted to the free nucleoside 9-β-D-arabinosyl-2-fluoroadenine (F-ara-A) which enters cells and accumulates mainly as the 5′-triphosphate, F-ara-ATP. The rate-limiting step in the formation of triphosphate is conversion of F-ara-A to its monophosphate, which is catalyzed by deoxycytidine kinase. Although F-ara-A is not a good substrate for this enzyme, the high specific activity of this protein results in efficient phosphorylation of F-ara-A in certain tissues. F-ara-ATP has multiple mechanisms of action, which are mostly directed toward DNA. These include inhibition of ribonucleotide reductase, incorporation into DNA resulting in repression of further DNA polymerisation, and inhibition of DNA ligase and DNA primase. Collectively these actions affect DNA synthesis, which is the major mechanism of F-ara-A-induced cytotoxicity Secondarily, incorporation into RNA and inhibition of transcription has been shown in cell lines.With the standard dose of fludarabine (25 to 30 mg/m2/day given over 30 minutes for 5 days), plasma concentrations of about 3 μmol/L F-ara-A are achieved at the end of each infusion. Serial sampling of leukaemia cells from patients receiving these standard doses of fludarabine has demonstrated that the peak concentrations of F-ara-ATP are achieved 4 hours after start of fludarabine infusion. Although there is heterogeneity among individuals with respect to rate of F-ara-ATP accumulation, the peak concentrations are generally proportional to the dose of the drug. Knowledge of the plasma pharmacokinetics of its principal nucleoside metabolite F-ara-A, and the cellular pharmacology of the proximal active metabolite, F-ara-ATP, has provided some understanding of the activity of fludarabine when used as a single agent. Preclinical studies directed toward learning the mechanisms of action of this agent have formed the basis for several mechanism-based strategies for its combination and scheduling with other agents.As a single agent fludarabine has been effective for the indolent leukaemias. Biochemical modulation strategies resulted in enhanced accumulation of cytarabine triphosphate and led to the use of fludarabine for the treatment of acute leukaemias. Combination of fludarabine with DNA damaging agents to inhibit DNA repair processes has been highly effective for indolent leukaemias and lymphomas. The current review brings together knowledge of the mechanisms of fludarabine, the state of understanding of the plasma pharmacokinetics, and cellular pharmacodynamics of fludarabine nucleotides. This may be useful in the design of future therapeutic approaches.

Research progress on pharmacokinetics of fludarabine and its synergistic effect with cytarabine

FLAG Regimen in Treatment of Relapsed/refractory Acute Leukemia

Fludarabine combined with colony-stimulating factor and cytarabine regimen for treatment of refractory or relapsed acute myeloid leukemia

A novel alkylating deacetylase inhibitor molecule EDO-S101 in combination with cytarabine synergistically enhances apoptosis of acute myeloid leukemia cells

Retrospective Comparison of Fludarabine in Combination with Intermediate-Dose Cytarabine Versus High-Dose Cytarabine As Consolidation Therapies for Acute Myeloid Leukemia.

Fludarabine and Ara-C Combination for Treatment of Adult Acute Myelogenous Leukemia: Pharmacokinetic and Pharmacodynamic Effects

Cellular and Clinical Pharmacology of Fludarabine

Efficacy and Safety Evaluation of Fludarabine-Based Chemotherapy Regimen for Patients with Non-Hodgkin Lymphoma A Meta-Analysis

Efficacy and Safety of Fludarabine Combined with Cytarabine in the Treatment of Patients with Relapsed and Refractory Acute Lymphoblastic Leukemia (ALL).

New Therapeutic Strategy of Fludarabine-Resistant Relapsed and Refractory Chronic Lymphocytic Leukemia

[Clinical Study on Fludarabine Combined with Cytarabine Regimen in the Treatment of Patients with Refractory and Relapsed Acute Myeloid Leukemia].

Effect of fludarabine on treatment of patients with chronic lymphocytic leukemia and its influence on survival rate

Effect of fludarabine combined with cytarabine on the viability and metabolic enzymes of HL-60 cells

Primary Clinical Study of FA Regimen As Consolidation Therapy for Patients with Acute Myeloid Leukemia

Synergistic effect of the combination of nanoparticulate Fe3O4 and Au with daunomycin on K562/A02 cells.

The Therapeutic Effects of FLAG Regime for Refractory and Relapsing Acute Leukemia

Influence of Fludarabine on Pharmacokinetics and Pharmacodynamics of Cytarabine: Implications for a Continuous Infusion Schedule.

Leukemia: A model for drug development

Clinical study of Fludarabine-based combination chemotherapy for non-Hodgkin lymphoma patients

Fludarabine Inhibits DNA Replication: A Rationale for Its Use in the Treatment of Acute Leukemias

Applying Of Fludarabine In One Patient With Cll/Pl Prolymphocytic Transformation - One Case Report.